Fusion Pharmaceuticals Inc logo

FUSN - Fusion Pharmaceuticals Inc News Story

$8.51 0.3  3.7%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £250.8m
Enterprise Value £87.3m
Revenue £n/a
Position in Universe 4090th / 7008

BRIEF-Fusion Pharma, AstraZeneca To Jointly Develop Radiopharmaceuticals, Combination Therapies

Mon 2nd November, 2020 12:07pm
Nov 2 (Reuters) - AstraZeneca PLC  AZN.L :
    * FUSION PHARMACEUTICALS ANNOUNCES COLLABORATION WITH
ASTRAZENECA
TO DEVELOP AND COMMERCIALIZE NEXT-GENERATION
RADIOPHARMACEUTICALS AND COMBINATION THERAPIES
    * FUSION PHARMACEUTICALS INC - AGREEMENT INCLUDES AN UPFRONT
PAYMENT FROM ASTRAZENECA, AS WELL AS FUTURE DEVELOPMENT
MILESTONE AND OTHER PAYMENTS
    * FUSION PHARMACEUTICALS INC - AGREEMENT INCLUDES AN UPFRONT
PAYMENT FROM ASTRAZENECA, AS WELL AS FUTURE DEVELOPMENT
MILESTONE AND OTHER PAYMENTS
    * FUSION PHARMACEUTICALS INC - FUSION AND ASTRAZENECA WILL
JOINTLY
DISCOVER, DEVELOP AND HAVE OPTION TO CO-COMMERCIALIZE NOVEL TATS
IN UNITED STATES
    * FUSION PHARMACEUTICALS INC - BOTH COMPANIES WILL HAVE A
50/50
PROFIT AND LOSS SHARE ON A WORLDWIDE BASIS.
    * FUSION PHARMACEUTICALS INC - COMPANIES WILL ALSO EVALUATE
POTENTIAL COMBINATION STRATEGIES INVOLVING EXISTING ASSETS IN
THEIR RESPECTIVE PORTFOLIOS
    * FUSION PHARMACEUTICALS - FUSION WILL CONDUCT PRECLINICAL
DEVELOPMENT. ASTRAZENECA WILL CONDUCT AND FUND CLINICAL
DEVELOPMENT OF COMBINATION THERAPIES

Source text for Eikon:  ID:nCNW58H9za 
Further company coverage:  AZN.L 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.